View Item 

Show simple item record

Correlates and Responsiveness to Change of Measures of Skin and Musculoskeletal Disease in Early Diffuse Systemic Sclerosis
dc.contributor.authorWiese, Alexandra B.en_US
dc.contributor.authorBerrocal, Veronica J.en_US
dc.contributor.authorFurst, Daniel E.en_US
dc.contributor.authorSeibold, James R.en_US
dc.contributor.authorMerkel, Peter A.en_US
dc.contributor.authorMayes, Maureen D.en_US
dc.contributor.authorKhanna, Dineshen_US
dc.date.accessioned2014-11-04T16:35:23Z
dc.date.availableWITHHELD_13_MONTHSen_US
dc.date.available2014-11-04T16:35:23Z
dc.date.issued2014-11en_US
dc.identifier.citationWiese, Alexandra B.; Berrocal, Veronica J.; Furst, Daniel E.; Seibold, James R.; Merkel, Peter A.; Mayes, Maureen D.; Khanna, Dinesh (2014). "Correlates and Responsiveness to Change of Measures of Skin and Musculoskeletal Disease in Early Diffuse Systemic Sclerosis." Arthritis Care & Research 66(11): 1731-1739.en_US
dc.identifier.issn2151-464Xen_US
dc.identifier.issn2151-4658en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/109290
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherErlbaumen_US
dc.titleCorrelates and Responsiveness to Change of Measures of Skin and Musculoskeletal Disease in Early Diffuse Systemic Sclerosisen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelGeriatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/109290/1/acr22339.pdf
dc.identifier.doi10.1002/acr.22339en_US
dc.identifier.sourceArthritis Care & Researchen_US
dc.identifier.citedreferenceCohen J. A power primer. Psychol Bull 1992; 112: 155 – 9.en_US
dc.identifier.citedreferenceKhanna D, Merkel PA. Outcome measures in systemic sclerosis: an update on instruments and current research. Curr Rheumatol Rep 2007; 9: 151 – 7.en_US
dc.identifier.citedreferenceClements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high‐dose versus low‐dose penicillamine trial. Arthritis Rheum 2000; 43: 2445 – 54.en_US
dc.identifier.citedreferenceAmjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, et al. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double‐blind, randomized controlled trials. Arthritis Rheum 2009; 60: 2490 – 8.en_US
dc.identifier.citedreferenceMerkel PA, Silliman NP, Denton CP, Furst DE, Khanna D, Emery P, et al, for the CAT‐192 Research Group and the Scleroderma Clinical Trials Consortium. Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. Arthritis Rheum 2008; 59: 699 – 705.en_US
dc.identifier.citedreferenceKissin EY, Schiller AM, Gelbard RB, Anderson JJ, Falanga V, Simms RW, et al. Durometry for the assessment of skin disease in systemic sclerosis. Arthritis Rheum 2006; 55: 603 – 9.en_US
dc.identifier.citedreferenceFries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137 – 45.en_US
dc.identifier.citedreferenceCole JC, Khanna D, Clements PJ, Seibold JR, Tashkin DP, Paulus HE, et al. Single‐factor scoring validation for the Health Assessment Questionnaire‐disability index (HAQ‐DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. Qual Life Res 2006; 15: 1383 – 94.en_US
dc.identifier.citedreferenceKhanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, et al. Responsiveness of the SF‐36 and the Health Assessment Questionnaire disability index in a systemic sclerosis clinical trial. J Rheumatol 2005; 32: 832 – 40.en_US
dc.identifier.citedreferenceClements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, et al. The disability index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high‐dose versus low‐dose penicillamine in systemic sclerosis trial. Arthritis Rheum 2001; 44: 653 – 61.en_US
dc.identifier.citedreferenceKhanna PP, Furst DE, Clements PJ, Maranian P, Indulkar L, Khanna D. Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial. Rheumatology (Oxford) 2010; 49: 955 – 9.en_US
dc.identifier.citedreferenceCohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): Erlbaum; 1988.en_US
dc.identifier.citedreferenceMedsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis [review]. Clin Exp Rheumatol 2003; Suppl 29: S42 – 6.en_US
dc.identifier.citedreferenceHudson M, Steele R, Lu Y, Thombs BD, Panopalis P, Baron M. Clinical correlates of self‐reported physical health status in systemic sclerosis. J Rheumatol 2009; 36: 1226 – 9.en_US
dc.identifier.citedreferenceHudson M, Impens A, Baron M, Seibold JR, Thombs BD, Walker JG, et al. Discordance between patient and physician assessments of disease severity in systemic sclerosis. J Rheumatol 2010; 37: 2307 – 12.en_US
dc.identifier.citedreferenceAu K, Mayes MD, Maranian P, Clements PJ, Khanna D, Steen VD, et al. Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study. Arthritis Care Res (Hoboken) 2010; 62: 1772 – 8.en_US
dc.identifier.citedreferenceKhanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, et al, for the relaxin investigators and the Scleroderma Clinical Trials Consortium. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double‐blind, placebo‐controlled trial. Arthritis Rheum 2009; 60: 1102 – 11.en_US
dc.identifier.citedreferenceSteen VD. Clinical manifestations of systemic sclerosis. Semin Cutan Med Surg 1998; 17: 48 – 54.en_US
dc.identifier.citedreferenceKhanna D, Tsevat J. Health‐related quality of life: an introduction [review]. Am J Manag Care 2007; 9: S218 – 23.en_US
dc.identifier.citedreferenceGladue H, Furst DE, Berrocal V, Seibold JR, Merkel PA, Mayes MD, et al. Comparison of baseline characteristics of the Combined Response Index for Systemic Sclerosis (CRISS) cohort to patients enrolled in clinical trials of diffuse systemic sclerosis [abstract]. Arthritis Rheum 2012; 64: 1464.en_US
dc.identifier.citedreferenceSubcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581 – 90.en_US
dc.identifier.citedreferenceLeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202 – 5.en_US
dc.identifier.citedreferenceMura G, Bhat KM, Pisano A, Licci G, Carta M. Psychiatric symptoms and quality of life in systemic sclerosis. Clin Pract Epidemiol Ment Health 2012; 8: 30 – 5.en_US
dc.identifier.citedreferenceDanieli E, Airo P, Bettoni L, Cinquini M, Antonioli CM, Cavazzana I, et al. Health‐related quality of life measured by the Short‐Form 36 (SF‐36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clin Rheumatol 2005; 24: 48 – 54.en_US
dc.identifier.citedreferenceDel Rosso A, Boldrini M, D'Agostino D, Placidi GP, Scarpato A, Pignone A, et al. Health‐related quality of life in systemic sclerosis as measured by the Short Form 36: relationship with clinical and biologic markers. Arthritis Rheum 2004; 51: 475 – 81.en_US
dc.identifier.citedreferenceKallen MA, Mayes MD, Kriseman YL, de Achaval SB, Cox VL, Suarez‐Almazor ME. The symptom burden index: development and initial findings from use with patients with systemic sclerosis. J Rheumatol 2010; 37: 1692 – 8.en_US
dc.identifier.citedreferenceDe Achaval S, Kallen MA, Mayes MD, Lopez‐Olivo MA, Suarez‐Almazor ME. Use of the patient‐generated index in systemic sclerosis to assess patient‐centered outcomes. J Rheumatol 2013; 40: 1337 – 43.en_US
dc.identifier.citedreferenceBassel M, Hudson M, Taillefer SS, Schieir O, Baron M, Thombs BD. Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology (Oxford) 2011; 50: 762 – 7.en_US
dc.identifier.citedreferenceVan Lankveld WG, Vonk MC, Teunissen H, van der Hoogen FH. Appearance self‐esteem in systemic sclerosis: subjective experience of skin deformity and its relationship with physician‐assessed skin involvement, disease status and psychological variables. Rheumatology (Oxford) 2007; 46: 872 – 6.en_US
dc.identifier.citedreferenceSuarez‐Almazor ME, Kallen MA, Roundtree AK, Mayes M. Disease and symptom burden in systemic sclerosis: a patient perspective. J Rheumatol 2007; 34: 1718 – 26.en_US
dc.identifier.citedreferenceKhanna D, Distler O, Avouac J, Behrens F, Clements PJ, Denton C, et al. Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS). J Rheumatol 2009; 36: 2356 – 61.en_US
dc.identifier.citedreferenceKhanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, et al. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis 2008; 67: 703 – 9.en_US
dc.identifier.citedreferenceClements PJ, Lachenbruch P, Siebold JR, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281 – 5.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
acr22339.pdf
Size:
106.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.